TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11950434
Drug: Maharishi Vedic
Normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maharishi Vedic Medicine (MVM)
Study: 11950434
Drug: Modern medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modern medicine (conventional dietary, exercise, and multivitamin approaches)
Study: 11950434
Drug: Maharishi Vedic
Normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maharishi Vedic Medicine (MVM) for high-risk subjects
Study: 11950434
Drug: Modern medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modern medicine for high-risk subjects
Study: 11950434
Drug: Maharishi Vedic
Normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maharishi Vedic Medicine (MVM) overall
Study: 8590577
Drug: Albendazole sulphoxide
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole sulphoxide (ABZS) administered orally
Study: 29346367
Drug: Albendazole (ABZ)
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole (ABZ) administered orally
Study: 81655
Drug: Inosiplex (drug-treated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inosiplex (drug-treated patients)
Study: 31050628
Drug: Iclaprim with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iclaprim with MIC > 8 µg/ml
Study: 23458162
Drug: Veriset™ haemostatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veriset™ haemostatic patch
Study: 23458162
Drug: Fibrin sealant
Normalized name: FIBRIN SEALANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin sealant patch (TachoSil(®))
Study: 21191313
Drug: Tailored individual
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tailored individual doses of radioiodine (¹³¹I) and low-dose antithyroid drug (ATD)
Study: 21191313
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with fixed dose of radioiodine set as 2.96 MBq/g of thyroid
Study: 21191313
Drug: Low-dose ATD
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ATD used in study group
Study: 12682825
Drug: benfluorex (150-450
Approvals — FDA: no, EMA: no, PMDA: no
Description: benfluorex (150-450 mg/day)
Study: 10548199
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline 7.2%-hydroxyethyl starch 6% solution (HS-HES group)
Study: 10548199
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline 7.2% solution (HS group)
Study: 10548199
Drug: Hydroxyethyl starch
Normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl starch 6% solution (HES group)
Study: 8913317
Drug: Chlorambucil (before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorambucil (before and after treatment)
Study: 7199345
Drug: Remid preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remid preparation of allopurinol, 300 mg p.o. dose
Study: 7199345
Drug: Standard preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preparation of allopurinol, 300 mg p.o. dose
Study: 21621629
Drug: Extracorporeal photopheresis
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal photopheresis (ECP) administered 3 times during week 1, then twice weekly until week 12, followed by 2 treatments monthly until week 24.
Study: 16568198
Drug: Tropisetron-Propofol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron-Propofol (5 mg tropisetron and 0.5 mg/kg propofol)
Study: 12937042
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (fish oil capsules rich in DHA)
Study: 12937042
Drug: Placebo supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplementation (placebo capsules)
Study: 21122499
Drug: Budesonide-MMX® 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide-MMX® 9 mg tablets
Study: 10464783
Drug: Pravastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (20 mg/die)
Study: 10464783
Drug: Acetylcholine (ACh)
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylcholine (ACh) infusion in 4 patients
Study: 2142294
Drug: BN 52063
Normalized name: MVA-BN
DrugBank: Modified vaccinia ankara (DB15483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BN 52063 240 mg p.o. 3 hours before exercise challenge
Study: 2142294
Drug: BN 52063
Normalized name: MVA-BN
DrugBank: Modified vaccinia ankara (DB15483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BN 52063 5 mg by inhalation 30 minutes before exercise challenge
Study: 349439
Drug: Quinestrol 2
Normalized name: quinestrol
DrugBank: Quinestrol (DB04575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinestrol 2 mg single dose
Study: 349439
Drug: Tace 72
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tace 72 mg every 12 hours for 2 days
Study: 7115012
Drug: imipramine hydrochloride,
Normalized name: Imipramine Hydrochloride, 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: imipramine hydrochloride, 150 mg daily
Study: 7115012
Drug: amitriptyline hydrochloride,
Normalized name: Amitriptyline Hydrochloride, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: amitriptyline hydrochloride, 150 mg daily
Study: 30727721
Drug: Topotecan (1.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan (1.75 mg/m2 IV) and gemcitabine (starting dose 700 mg/m2 with increments of 100 mg/m2) administered on days 1, 8, and 15 every 28 days.
Study: 30504736
Drug: Aspirin therapy
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin therapy (80–325 mg)
Study: 26900146
Drug: Teriparatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (20 mcg subcutaneously daily)
Study: 26964731
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Teriparatide and Denosumab
Study: 627129
Drug: Intravenous labetalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous labetalol (1.5 mg/kg)
Study: 31349862
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg daily aspirin
Study: 27023008
Drug: Twice‐daily detemir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice‐daily detemir
Study: 22608262
Drug: Active chemotherapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active chemotherapy
Study: 15893011
Drug: Topotecan (T)
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topotecan (T) 1.0 mg/m2 d 1-5 and Cisplatin (DDP) 75 mg/m2 d 5 (arm A)
Study: 15893011
Drug: Topotecan (T)
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topotecan (T) 1.5 mg/m2 d 1-3 and Cisplatin (DDP) 75 mg/m2 d 3 (arm B)
Study: 11826245
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment (Nutropin, 1 mg/m2/day)
Study: 7786960
Drug: L-365,260, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-365,260, 30 mg qid
Study: 375401
Drug: Butorphanol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol (2 mg)
Study: 375401
Drug: Butorphanol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol (4 mg)
Study: 24359265
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (FPS and CO2 FS)
Study: 24359265
Drug: Treatment within
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment within 3 years of scar development
Study: 24359265
Drug: Treatment >3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment >3 years after scar development
Study: 19789403
Drug: Hawthorn 450
Normalized name: Hawthorn 450 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hawthorn 450 mg twice daily
Study: 12085156
Drug: Risedronate 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 50 mg once a week
Study: 11453887
Drug: Perindopril (4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4, 8, 16 mg) in HV; 4 mg in CHF patients
Study: 9743163
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (BDP, TA, and placebo)
Study: 3208513
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 10 mg x 2 for seven days
Study: 3208513
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 25 mg x 2 for seven days
Study: 3208513
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 50 mg x 2 for seven days
Study: 29925684
Drug: Intranasal carbetocin
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal carbetocin
Study: 20880120
Drug: Bortezomib 1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.3 mg/m² on days 1, 4, 8, and 11 of a 3-week cycle with rituximab 375 mg/m² on day 1 (21 patients)
Study: 20880120
Drug: Bortezomib 1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.6 mg/m² and rituximab on days 1, 8, 15, and 22 of a 5-week cycle (with rituximab given only in cycles 1 and 4) (21 patients)
Study: 18397330
Drug: Metronidazole for
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole for 5 days, 20 mg/kg/day for children and 1.5 g/day for adults
Study: 18397330
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of ornidazole, 30 mg/kg for children and 2 g for adults
Study: 10568908
Drug: Concurrent steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent steroid use allowed in seven trials.
Study: 10568908
Drug: Post-randomization steroid
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-randomization steroid use instructions specified in 3 of 14 trials where steroids were not part of the intervention.
Study: 10568908
Drug: Steroid dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid dosing during the intervention reported as a secondary outcome measure in four trials.
Study: 10568908
Drug: Free concurrent
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free concurrent steroid use during the intervention allowed in 11 RCTs.
Study: 3023712
Drug: Oral cyclosporine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclosporine, 14 mg/kg/d
Study: 19583558
Drug: Hormone treatment
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone treatment close to the menopausal transition
Study: 16874014
Drug: COMBAT protocol
Normalized name: Provita Combat
Approvals — FDA: no, EMA: no, PMDA: no
Description: COMBAT protocol (daily celecoxib, 13-cisretinoic acid, metronomic temozolomide, low-dose etoposide)
Study: 10840169
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of exogenous testosterone
Study: 2166452
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (EM) with positive HSV serology
Study: 7265455
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment (drug group)
Study: 14660506
Drug: High carbohydrate
Normalized name: High carbohydrate food
Approvals — FDA: no, EMA: no, PMDA: no
Description: High carbohydrate diet (HCHO) at 8.5 g CHO x kg(‐1) x day(‐1)
Study: 14660506
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (Con) at 5.4 g CHO x kg(‐1) x day(‐1)
Study: 9407678
Drug: Intermittent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bolus epidural morphine (3 mg every 8 hours)
Study: 9407678
Drug: Patient-controlled epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled epidural analgesia (PCEA) with morphine (2 mg bolus, 0.15 mg/h)
Study: 8143997
Drug: rectal cisapride
Normalized name: Cisapride
DrugBank: Cisapride (DB00604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rectal cisapride (30 mg three times daily)
Study: 8143997
Drug: meperidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: meperidine (1 mg/kg over 3 hours)
Study: 30036412
Drug: Systemic steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic steroid treatment
Study: 31474354
Drug: Single-agent niraparib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent niraparib
Study: 26163202
Drug: Lobeglitazone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lobeglitazone (0.5 mg) administered with amlodipine (10 mg)
Study: 26163202
Drug: Amlodipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (10 mg) administered with lobeglitazone (0.5 mg)
Study: 24294746
Drug: M+M+G (Metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: M+M+G (Metronidazole + Metronidazole + Lactobacillus casei var rhamnosus - Lcr 35)
Study: 11701431
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg testosterone enanthate
Study: 11701431
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg testosterone enanthate
Study: 26706665
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss intervention and Metformin
Study: 24886455
Drug: Mechanical traction
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical traction (12 treatments over six consecutive weeks)
Study: 17508190
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg hyperbaric 0.5% levobupivacaine
Study: 17508190
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg hyperbaric 0.5% levobupivacaine
Study: 17508190
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg hyperbaric 0.5% levobupivacaine
Study: 17508190
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg vs 12.5 mg hyperbaric 0.5% levobupivacaine
Study: 16371677
Drug: Schoolwide intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Schoolwide intervention that incorporated universal and targeted treatment
Study: 8555131
Drug: One single
Normalized name: Risperidone Single-Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single pre‐operative dose of metronidazole (10 mg/kg)
Study: 8555131
Drug: Both metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both metronidazole (20 mg/kg) and cefuroxime (50 mg/kg) in a single preoperative dose
Study: 8555131
Drug: Preoperative antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative antibiotics (metronidazole and cefuroxime)
Study: 1975490
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine injections as needed
Study: 7150
Drug: Gallamine triethiodide
Normalized name: Gallamine Triethiodide
DrugBank: Gallamine triethiodide (DB00483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallamine triethiodide (40 mg)
Study: 31869726
Drug: G1: 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: G1: 24 sets of five repetitions with 30 s rest at 80% of one repetition maximum using Iowa Oral Performance Instrument (IOPI) per day
Study: 31869726
Drug: G2: Forceful
Approvals — FDA: no, EMA: no, PMDA: no
Description: G2: Forceful swallow of 5 mL of water in a neutral posture every 10 s for 20 min per day
Study: 31869726
Drug: G3: 5
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: G3: 5 mL of water swallowing exercise in chin-down posture every 10 s for 20 min per day
Study: 17891897
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) 200 mg administered at specified times during Days 2-4
Study: 11161370
Drug: DepoCyte 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DepoCyte 50 mg injected once every 2 weeks for one month of induction therapy
Study: 11161370
Drug: DepoCyte 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DepoCyte 50 mg
Study: 9002389
Drug: White light
Normalized name: Light White Mineral Oil
DrugBank: Light mineral oil (DB11579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: White light treatment for 2 weeks
Study: 9002389
Drug: Placebo red
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo red light treatment for 2 weeks
Study: 7989947
Drug: Chemotherapy response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy response
Study: 28544687
Drug: Local physiotherapy
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local physiotherapy and oral nonsteroidal anti‐inflammatory drugs
Study: 27869712
Drug: Pterocarpan-high soybean
Normalized name: SOYBEAN
DrugBank: Soybean (DB10568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pterocarpan-high soybean leaf extract (PT) 2 g/day for 12 weeks
Study: 27869712
Drug: Placebo (starch,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (starch, 3 g/day) for 12 weeks
Study: 20679774
Drug: L-BIS group
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-BIS group (BIS values 20-30)
Study: 20679774
Drug: L-BIS group
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-BIS group
Study: 12439209
Drug: Single-dose nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose nevirapine (NVP)
Study: 16052084
Drug: Maternal CD4
Normalized name: lisocabtagene maraleucel
DrugBank: Lisocabtagene maraleucel (DB16582)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal CD4 cell count < 500 x 10(6) cells/l
Study: 16052084
Drug: Maternal viral
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal viral load > 50 000 copies/ml
Study: 2021986
Drug: Epidural nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural nalbuphine (0.075-0.3 mg.kg-1)
Study: 2021986
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (0.1 mg.kg-1)
Study: 6177846
Drug: Naldecon (antihistamine-decongestant)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naldecon (antihistamine-decongestant)
Study: 25233654
Drug: Fire needling
Normalized name: Fire Out
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fire needling therapy
Study: 25233654
Drug: Oxycycline tablets
Normalized name: Doxycycline Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycycline tablets (100 mg, twice daily for 20 days) with external application of adapalene gel before sleep
Study: 25233654
Drug: Oxycycline tablets
Normalized name: Doxycycline Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycycline tablets
Study: 22608570
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids (OCSs), more than 2 courses per year
Study: 22608570
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids (OCSs), less than or equal to 2 courses per year
Study: 22608570
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids (OCSs)
Study: 20807066
Drug: Single-dose, immediate-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose, immediate-release dexmethylphenidate (dMPH)
Study: 12637133
Drug: Pharmacokinetic dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetic dosing (n=43)
Study: 12637133
Drug: Fixed once‐daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed once‐daily dosing (n=38)
Study: 10982163
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate supplement alone (750 mg daily)
Study: 10982163
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate plus calcitriol (750 mg calcium carbonate + 0.5 microg calcitriol daily)
Study: 1480877
Drug: Test drug
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug given once daily
Study: 6198064
Drug: High-dose cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cisplatin (120 mg/m2, monthly) combined with vinblastine and bleomycin
Study: 6198064
Drug: Low-dose cisplatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cisplatin (15 mg/m2, daily X 5 monthly) combined with vinblastine and bleomycin
Study: 27427235
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated equine estrogens (CEE) daily for 28 days
Study: 22327404
Drug: Lipid/heparin emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid/heparin emulsion (Intralipid) infusion
Study: 22327404
Drug: Heparin only
Normalized name: Heparin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin only infusion
Study: 16139778
Drug: Individually tailored
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually tailored behavioral medicine intervention
Study: 11966744
Drug: Lyndiol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyndiol (2.5 mg lynestrenol + 0.05 mg ethinyl‐oestradiol)
Study: 11966744
Drug: Pill-free period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill-free period
Study: 7558212
Drug: Intraumbilical oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraumbilical oxytocin (10 units in 20 ml saline)